The diverse functions of the PD1 inhibitory pathway - PubMed (original) (raw)
Review
. 2018 Mar;18(3):153-167.
doi: 10.1038/nri.2017.108. Epub 2017 Nov 13.
Affiliations
- PMID: 28990585
- DOI: 10.1038/nri.2017.108
Review
The diverse functions of the PD1 inhibitory pathway
Arlene H Sharpe et al. Nat Rev Immunol. 2018 Mar.
Abstract
T cell activation is a highly regulated process involving peptide-MHC engagement of the T cell receptor and positive costimulatory signals. Upon activation, coinhibitory 'checkpoints', including programmed cell death protein 1 (PD1), become induced to regulate T cells. PD1 has an essential role in balancing protective immunity and immunopathology, homeostasis and tolerance. However, during responses to chronic pathogens and tumours, PD1 expression can limit protective immunity. Recently developed PD1 pathway inhibitors have revolutionized cancer treatment for some patients, but the majority of patients do not show complete responses, and adverse events have been noted. This Review discusses the diverse roles of the PD1 pathway in regulating immune responses and how this knowledge can improve cancer immunotherapy as well as restore and/or maintain tolerance during autoimmunity and transplantation.
Similar articles
- An optimized protocol for the in vitro generation and functional analysis of human PD1/PD-L1 signal.
Khedri M, Abnous K, Rafatpanah H, Ramezani M. Khedri M, et al. J Recept Signal Transduct Res. 2018 Feb;38(1):31-36. doi: 10.1080/10799893.2017.1414843. Epub 2017 Dec 18. J Recept Signal Transduct Res. 2018. PMID: 29252078 - Coinhibitory Pathways in Immunotherapy for Cancer.
Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Baumeister SH, et al. Annu Rev Immunol. 2016 May 20;34:539-73. doi: 10.1146/annurev-immunol-032414-112049. Epub 2016 Feb 25. Annu Rev Immunol. 2016. PMID: 26927206 Review. - PDL-1/PD1 inhibitors: antibody or antinobody?
Aoun F, Rassy EE, Assi T, Kattan J. Aoun F, et al. Future Oncol. 2017 Aug;13(19):1669-1671. doi: 10.2217/fon-2017-0215. Epub 2017 Aug 23. Future Oncol. 2017. PMID: 28831825 No abstract available. - Immunotherapy for head and neck cancers: an update and future perspectives.
Doescher J, Laban S, Schuler PJ, Brunner C, Hoffmann TK. Doescher J, et al. Immunotherapy. 2019 May;11(7):561-564. doi: 10.2217/imt-2019-0022. Immunotherapy. 2019. PMID: 30943860 Review. No abstract available. - [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
Guilleminault L, Carmier D, Heuzé-Vourc'h N, Diot P, Pichon E. Guilleminault L, et al. Rev Pneumol Clin. 2015 Feb;71(1):44-56. doi: 10.1016/j.pneumo.2014.11.004. Epub 2015 Feb 14. Rev Pneumol Clin. 2015. PMID: 25687821 Review. French.
Cited by
- Gal-3 blocks the binding between PD-1 and pembrolizumab.
Greisen SR, Bendix M, Nielsen MA, Pedersen K, Jensen NH, Hvid M, Mikkelsen JH, Drace T, Boesen T, Steiniche T, Schmidt H, Deleuran B. Greisen SR, et al. J Immunother Cancer. 2024 Oct 2;12(10):e009952. doi: 10.1136/jitc-2024-009952. J Immunother Cancer. 2024. PMID: 39357979 Free PMC article. - PD-L1 as a Prognostic Factor in Early-Stage Colon Carcinoma within the Immunohistochemical Molecular Subtype Classification.
Azcue P, Encío I, Guerrero Setas D, Suarez Alecha J, Galbete A, Mercado M, Vera R, Gomez-Dorronsoro ML. Azcue P, et al. Cancers (Basel). 2021 Apr 17;13(8):1943. doi: 10.3390/cancers13081943. Cancers (Basel). 2021. PMID: 33920689 Free PMC article. - LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity.
Ngiow SF, Manne S, Huang YJ, Azar T, Chen Z, Mathew D, Chen Q, Khan O, Wu JE, Alcalde V, Flowers AJ, McClain S, Baxter AE, Kurachi M, Shi J, Huang AC, Giles JR, Sharpe AH, Vignali DAA, Wherry EJ. Ngiow SF, et al. Cell. 2024 Aug 8;187(16):4336-4354.e19. doi: 10.1016/j.cell.2024.07.018. Cell. 2024. PMID: 39121847 - Adjuvant immunotherapy improves recurrence-free and overall survival following surgical resection for intermediate/advanced hepatocellular carcinoma a multicenter propensity matching analysis.
Xu X, Wang MD, Xu JH, Fan ZQ, Diao YK, Chen Z, Jia HD, Liu FB, Zeng YY, Wang XM, Wu H, Qiu W, Li C, Pawlik TM, Lau WY, Shen F, Lv GY, Yang T. Xu X, et al. Front Immunol. 2024 Jan 8;14:1322233. doi: 10.3389/fimmu.2023.1322233. eCollection 2023. Front Immunol. 2024. PMID: 38268916 Free PMC article. - Matrix metalloproteinase 1 is a poor prognostic biomarker for patients with hepatocellular carcinoma.
Xu L, Yang H, Yan M, Li W. Xu L, et al. Clin Exp Med. 2023 Oct;23(6):2065-2083. doi: 10.1007/s10238-022-00897-y. Epub 2022 Sep 28. Clin Exp Med. 2023. PMID: 36169759
References
- Immunity. 2011 Sep 23;35(3):400-12 - PubMed
- Science. 2001 Jan 12;291(5502):319-22 - PubMed
- J Exp Med. 2012 Dec 17;209(13):2485-99 - PubMed
- Immunity. 2016 Feb 16;44(2):274-86 - PubMed
- Cell. 2015 Sep 10;162(6):1229-41 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials